Clinical trials: Antipsychotic Induced Weight Gain
Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain
Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial
The goal of this clinical trial is to learn whether dapagliflozin can help manage weight gain caused by antipsychotic medications in people aged 16 years or older who are receiving antipsychotic treatment and have developed…
- Trial name
- NCT07342764
- Testing
- Dapagliflozin, Metformin, Common Lifestyle Program
- Where
- Oman
- Volunteers
- 110 people
- Sponsor
- Sultan Qaboos University
Drug Induced Weight Gain
Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics
Atypical antipsychotics (AA) are broadly used to treat a variety of psychiatric and neurological disorders in children and adolescents. Weight gain is a common side effect of these drugs.
- Trial name
- NCT00845936
- Testing
- Metformin
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- BeerYaakov Mental Health Center
Schizophreniform Disorder, Bipolar I Disorder
Prevention of Weight Gain in Early Psychoses
The purpose of this study is to determine whether individuals with psychotic spectrum disorders ( Schizophrenia, Schizoaffective disorder,Schizophreniform Disorder, Bipolar Disorder (Type I),Bipolar Disorder (Type II),Major…
- Conditions
- Schizophreniform Disorder, Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder
- Trial name
- NCT01075295
- Testing
- Behavioural Intervention for the Prevention of Weight Gain, TAU
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Centre for Addiction and Mental Health
Weight Gain
Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
The purpose of this pilot study is to determine whether starting metformin in conjunction with a second-generation antipsychotic (SGA) and providing information about healthy eating and activity will prevent or reduce the amount…
- Trial name
- PREVENT (NCT00617240)
- Testing
- metformin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of North Carolina, Chapel Hill
Obesity, Weight Gain
Reducing Antipsychotic-Induced Weight Gain in Children With Metformin
Recent but limited short term studies have shown that Metformin can slow down weight gain in obese children and in children with psychotropic-induced weight gain, two distinct pediatric populations that are at risk for obesity…
- Conditions
- Obesity, Weight Gain, Psychotropic Induced Weight Gain
- Trial name
- GFMS (NCT01231074)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Nationwide Children's Hospital
High Risk MC4R Genotype, Low Risk MC4R Genotype
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
We will conduct a 12-week, randomized open label study, comparing usual care (UC) antipsychotic treatment (aripiprazole, quetiapine, risperidone) with ziprasidone (ZIP) in children and adolescents aged 13-18 years old.
- Conditions
- High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure
- Trial name
- NCT01844700
- Testing
- Ziprasidone, aripiprazole, quetiapine, or risperidone
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Northwell Health
Intellectual Disability, Developmental Disability
Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
People with IDD (intellectual and developmental disability) have very high rates of obesity and die prematurely from cardiometabolic disease.
- Conditions
- Intellectual Disability, Developmental Disability, Obesity
- Trial name
- METIDD (NCT05744479)
- Testing
- Metformin, Lifestyle Intervention
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Centre for Addiction and Mental Health
Hyperprolactinemia, Weight Gain
Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia
This is a prospective, open-label study to evaluate the efficacy and safety in reducing antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole.
- Conditions
- Hyperprolactinemia, Weight Gain, Dyslipidemia
- Trial name
- NCT00541554
- Testing
- Abilify (aripiprazole)
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Autism Spectrum Disorder
A Study Looking at How Well Children With Autism Spectrum Disorder on Medications Like Having More Protein
Antipsychotic medications are commonly prescribed in children and adults with ASD (Curtin, Jojic \& Bandini, 2014). But weight gain has been known to be one of the less desirable effects of these medications, increasing one's…
- Trial name
- NCT03708614
- Testing
- Controlled energy diet with elevated protein intake
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Holland Bloorview Kids Rehabilitation Hospital